Company Active LTD

Company profile

Optibiotix Limited

Home - Optibiotix

Optibiotix Limited is a UK company with status active founded in 2012 based in Yorkshire and the Humber.

CRN
07992608
Founded
2012
Age
14

Overview

Legal name
OPTIBIOTIX LIMITED
Region
Yorkshire and the Humber
Registered address
INNOVATION CENTRE INNOVATION WAY
HESLINGTON
YORK
YO10 5DG
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

1 level 1 ultimate controller
1
Company Active LTD
Optibiotix Limited
CRN 07992608
2
Direct and ultimate controller Active PLC
Optibiotix Health PLC
CRN 05880755

Company events

Reference milestones and recent Companies House filing stream events.

7 events
14 Feb
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

31 Jan
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

25 Feb
2025

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzQ1NjM1ODk1NWFkaXF6a2N4

Published 25 Feb 2025 16:22

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

08 Oct
2024

Accounts With Accounts Type Total Exemption Full

Accounts PDF pending

AA | Transaction MzQzODE1NDE5NmFkaXF6a2N4 | Paper/PDF filed

Published 09 Oct 2024 06:08

15 Mar
2012

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2012
Funded years
2012, 2013
Age at first award
0 years

Projects

2013 GRD Proof of Market Lead participant

Novel synbiotic to address weight loss

1 Apr 2013 to 31 Jul 2013

Awarded
£24,193
Total cost £40,322

indigenous species and strains of bacteria that make up the human microbiome, providing greater insight into the role of gut microbial flora. This has generated interest in the development of synbiotics to modify the human microbiome to support weight loss as part of a diet and exercise weight-loss program. Obesity has an adverse effect on health, leading...

2012 Vouchers Lead participant

Developing a novel food product for metabolic syndrome

1 Nov 2012 to 31 Mar 2013

Awarded
£5,000
Total cost £5,000

Metabolic syndrome has been described as the world’s biggest public health problems with over 25% of adults in the UK and USA suffering. More than 2.8 m people die each year as a result of metabolic syndrome. Its occurrence is linked to increasing rates of obesity with weight management programs the cornerstone of management of metabolic syndrome. Limitat...

Product types

GRD Proof of Market Vouchers